🇺🇸 FDA
Patent

US 10456404

Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods

granted A61KA61K31/4985A61K31/506

Quick answer

US patent 10456404 (Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods) held by United States Government as represented by the Department of Veterans Affairs expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States Government as represented by the Department of Veterans Affairs
Grant date
Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/4985, A61K31/506, A61K31/519, A61K31/53